What You Ought to Know:
– Vivodyne, an organization pioneering an solely human-focused preclinical course of, in the present day introduced it has raised $40M in new Sequence A funding led by Khosla Ventures, with participation from new traders Lingotto Investment Management, Helena Capital, Fortius Ventures, and current traders Kairos Ventures, CS Ventures, Bison Ventures, and MBX Capital.
– Vivodyne is essentially altering how therapies are examined earlier than human medical trials through the use of a complicated robotics and AI strategy on 1000’s of lab-grown, fully-functional human tissues. This methodology goals to considerably enhance the traditionally low success charges of medication transitioning from animal fashions to human trials.
Overcoming the Preclinical “Valley of Demise” with Human-Centric Testing
A staggering close to 95% of therapies that present promise in animal fashions throughout preclinical testing finally fail in human medical trials. This excessive failure charge highlights a important flaw in conventional drug growth: therapies are optimized for animal biology with out human-specific refinement. Vivodyne’s platform straight addresses this by permitting the identical refinement course of however on complicated human tissues, aiming to provide “people-ready” drug candidates for the primary time.
“Vivodyne is essentially altering how medicine transfer from the lab bench to human trials,” stated Andrei Georgescu, Ph.D., CEO and co-founder of Vivodyne. “A mannequin that’s solely predictive 5% of the time isn’t a mannequin. We’re redefining success in drug discovery by overcoming the constraints which have stalled scientific progress for many years”. He additional added, “Pharma has waited a long time for scalable human information earlier than medical trials. We’re now producing information from tens of 1000’s of complicated human tissues, capturing immune responses and illness states that had been beforehand inaccessible. This unprecedented scale and determination unlock fully new avenues for drug growth”.
Robotics and AI Powering Unprecedented Scale in Human Tissue Evaluation
Vivodyne’s expertise allows large-scale testing on lab-grown human tissues that may recapitulate the complexity of human illness, resulting in extra correct and predictive outcomes than animal fashions. The corporate produces human multi-omic information, together with imaging, single-cell transcriptomics, and proteomics from greater than 10,000 impartial human-tissue experiments per robotic run. These lab-grown tissues are notably a thousand instances bigger than typical organoids, permitting for detailed, purposeful analyses of human drug responses.
The platform’s totally automated robotic workflow ensures reproducibility at an AI-scale throughput, reportedly producing extra dependable, human-relevant information yearly than all U.S. medical trials mixed.
Fueling Enlargement to Meet Surging Demand for Human-Related Knowledge
The brand new $40M financing will allow Vivodyne to scale its robotics and AI strategy considerably. A key a part of this growth contains opening a brand new 23,000-square-foot totally robotic laboratory at Genesis Marina in South San Francisco. This facility will considerably improve Vivodyne’s preclinical human testing capability, catering to the surging demand from world pharmaceutical shoppers. This demand has been additional spurred by current commitments from the FDA and NIH to maneuver away from less-predictive animal fashions in drug growth.
